Carlsmed Q1 Revenue $16.12M Beats Expectations
Reports Q1 revenue $16.12M, consensus $14.98M. "We began 2026 with strong momentum, delivering 58% year-over-year revenue growth, publishing meaningful clinical data, and debuting new products to continue to advance our mission of improved patient outcomes and reduced cost of healthcare," said Mike Cordonnier, Chairman and Chief Executive Officer of Carlsmed. "The publication of peer-reviewed data from a retrospective cohort study in Global Spine Journal demonstrates a 74% reduction in revision rates for aprevo, which represents one of the most significant advancements in reducing reoperations in adult spinal deformity over the past two decades. With our first full commercial quarter for aprevo Cervical and the anticipated launch of our corra patient-specific fixation portfolio later this year, we believe we are well positioned for continued growth and innovation throughout 2026."
